GlassScriptPhysician profile
Gino Bottino
NPI 1881705838
$4,461.43
in general payments reported to CMS, 2019-2025
43 companies · $404 in 2025
The $404 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,103 · 2020: $226 · 2021: $1,166 · 2022: $1,025 · 2024: $537 · 2025: $404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $941.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $941.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $495.74 | 2019-2025 | |
| Janssen Biotech, INC. | $398.23 | 2019-2025 | Erleada, Tecvayli, Darzalex |
| Astrazeneca Pharmaceuticals LP | $341.02 | 2021-2025 | Calquence, Enhertu, Lynparza |
| Astellas Pharma US INC | $242.45 | 2019-2022 | |
| Amgen INC. | $221.69 | 2019-2020 | |
| Lilly USA, LLC | $209.63 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $173.48 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Celgene Corporation | $148.40 | 2019-2022 | |
| Genentech USA, INC. | $147.59 | 2019-2022 | |
| Seagen INC. | $146.82 | 2021-2022 | |
| Incyte Corporation | $145.06 | 2019-2024 | Jakafi |
| E.R. Squibb & Sons, L.L.C. | $143.06 | 2019-2024 | Opdivo |
| Genzyme Corporation | $137.47 | 2019-2022 | |
| Epizyme, INC. | $131.89 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $130.04 | 2019-2025 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gino Bottino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.